《 人民日报 》（ 2025年09月08日 16 版） 本报南宁9月7日电 （记者庞革平）中国—东盟区域医药交易（集采）平台日前在广西南宁发布企业首 单跨境线上交易和结算，杭州中美华东制药有限公司通过该平台完成了一单与新加坡方的交易，标志着 该平台作为服务中国医药企业"出海"东盟国家和上合组织国家的便捷、安全通道已基本成熟。该平台于 2025年1月正式启动，是国家医疗保障局指导地方建设的首个跨境区域医药集采平台。 (责编：岳弘彬、牛镛) ...

据广西壮族自治区医疗保障局局长庞军介绍，目前，有114家中国头部医药企业和10家国外医药采购商 进驻平台。下一步，广西力争在平台推动面向东盟等双边多边医药规则互认上取得新突破，在平台推动 实施更多"小而美"医药民生项目上取得新突破。(完) 【东盟专线】中国—东盟区域医药交易平台完成企业首单跨境线上交易结算 （文章来源：中国新闻网） 中新社南宁9月4日电 (黄艳梅黄越)中国—东盟区域医药交易(集采)平台(下称"平台")企业首单跨境线上 交易发布仪式4日在广西南宁市举行，标志着中国首个跨境区域医药交易平台建设取得新突破。 杭州中美华东制药有限公司是首家通过平台实现线上跨境交易的中国医药企业。"平台是中国企业和东 盟国家采购方之间的'直通车'，为'出海'企业提供了便捷的交易全流程服务。我们企业完成了首单与新 加坡有关方面的交易，并成功供货我们生产的百令胶囊产品。"杭州中美华东制药有限公司董事陈波 说。 ...

Group 1 - The core point of the article is that Liaoning Chengda has seen a decrease in the number of shareholders and an increase in average shareholding quantity, while its average shareholding value remains below the industry average [1][2] - As of June 30, 2025, the number of shareholders for Liaoning Chengda is 66,011, a decrease of 3,580 or 5.14% from March 31, 2025 [1][2] - The average number of shares held per shareholder increased from 22,000 to 23,200, with an average shareholding value of 254,900 yuan [1][2] Group 2 - The stock price of Liaoning Chengda increased by 5.36% from March 31, 2025, to June 30, 2025, despite the decrease in the number of shareholders [1][2] - The average number of shareholders in the biopharmaceutical industry is 34,000, indicating that Liaoning Chengda's shareholder count is above the industry average [1] - During the same period, the net outflow of main funds was 237 million yuan, while retail investors saw a net inflow of 103 million yuan [2]

Core Viewpoint - Liaoning Chengda Co., Ltd. reported strong financial performance in the first half of 2025, with significant revenue and profit growth driven by its biopharmaceutical, financial investment, and trade sectors [1][2][3]. Financial Performance - In H1 2025, the company achieved operating revenue of 5.348 billion yuan and a net profit of 718 million yuan, marking a year-on-year increase of 56.18% [1]. - The financial investment segment, primarily from Guangfa Securities and China Insurance, generated investment income of 1.076 billion yuan and 86.3 million yuan, with year-on-year growth of 53.19% and 143.94%, respectively [7][8]. Biopharmaceutical Development - Chengda Biopharmaceutical achieved operating revenue of 707 million yuan and a net profit of 122 million yuan in H1 2025, with a 100% pass rate for vaccine product approvals [3]. - The company signed a cooperation agreement with a leading AI technology firm to establish an "AI + Vaccine R&D Joint Laboratory," enhancing its research capabilities [2]. Trade Sector Performance - The domestic and international trade segment reported operating revenue of 4.634 billion yuan, a year-on-year increase of 3.20%, and a net profit of 22.38 million yuan, up 40.52% [4]. - The company is focusing on strengthening team building, resource integration, and market opportunity capture in its trade operations [5]. Financial Strategy and Resource Optimization - The new management team has been actively optimizing the company's debt structure and financing capabilities, issuing short-term financing bonds at competitive rates [8]. - The company aims to enhance its core competitiveness and financial resilience through strategic resource allocation and financial tool utilization [8].

Group 1 - Company Liaoning Chengda announced that its subsidiary Xinjiang Baoming Mining has obtained mining licenses for oil shale in two areas, Wujiawan and Mutasi, in Xinjiang [1] - The company has confirmed the value of the mining rights based on resource value assessments, and will increase its investment in Xinjiang Baoming without additional cash input, maintaining a debt balance of 4.593 billion yuan after the capital increase [1] - Following the capital increase, the company's equity stake in Xinjiang Baoming will rise from 60.5% to 62%, while the profit-sharing ratio remains unchanged at 62% [1] Group 2 - For the year 2024, Liaoning Chengda's revenue composition is projected to be 84.87% from import and export trade, 14.85% from biopharmaceuticals, and 0.28% from other sources [2] - The current market capitalization of Liaoning Chengda is 20 billion yuan [3]

证券代码：600739 证券简称：辽宁成大 公告编号：2025－067 辽宁成大股份有限公司 第十一届董事会第六次会议决议公告 本议案已经公司董事会审计委员会审议通过。 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 二、关于修订《辽宁成大股份有限公司董事会秘书工作制度》的议案（详见 上海证券交易所网站） 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 三、关于修订《辽宁成大股份有限公司内幕信息及知情人管理制度》的议案 （详见上海证券交易所网站） 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 四、关于修订《辽宁成大股份有限公司担保业务管理制度》的议案（详见上 海证券交易所网站） 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司（以下简称"公司"）董事会于 2025 年 8 月 19 日以 书面和电子邮件方式发出召开第十一届董事会第六次会议的通知，会议于 2025 年 8 月 29 日在公司会议室以通讯方式召开并 ...

Core Points - The article outlines the management system for the resignation of directors and senior management at Liaoning Chengda Co., Ltd, aiming to ensure stability in corporate governance and protect the rights of shareholders [1][2]. Group 1: General Principles - The resignation management system is based on principles of legality, transparency, smooth transition, and protection of shareholder rights [1]. - The system applies to various resignation scenarios, including term expiration, voluntary resignation, dismissal, or other reasons [1]. Group 2: Resignation Procedures - Directors and senior management can resign before their term ends by submitting a written report, with the resignation effective upon receipt by the board [2]. - The company must complete the re-election of directors within 60 days if a resignation occurs, ensuring compliance with legal and regulatory requirements [2]. Group 3: Responsibilities and Obligations - Resigning directors and senior management must complete handover procedures and remain liable for their duties for six months post-resignation [4]. - They are required to maintain confidentiality regarding company secrets even after leaving [4]. Group 4: Shareholding Management - Directors and senior management are restricted from transferring 25% of their shares for six months after resignation, with exceptions for legal circumstances [5]. - Any commitments made regarding shareholding must be strictly adhered to by the resigning individuals [5]. Group 5: Accountability Mechanism - The company reserves the right to seek compensation from resigning directors and senior management for any losses incurred due to violations of laws or commitments [5]. - If any breaches of duty or unfulfilled commitments are discovered, the board will take necessary actions to hold individuals accountable [5]. Group 6: Miscellaneous - The system will be executed in accordance with relevant national laws and regulations, and the board is responsible for its interpretation and amendments [6].

Core Viewpoint - The report highlights the financial performance and operational challenges faced by Liaoning Cheng Da Co., Ltd. during the first half of 2025, with a focus on its four main business segments: pharmaceutical and medical, financial investment, domestic and international trade, and energy development. Financial Performance - The company reported a total revenue of 5.35 billion yuan, a decrease of 0.83% compared to the same period last year [5][6] - Total profit reached 816.12 million yuan, marking a significant increase of 65.64% year-on-year [5][6] - Net profit attributable to shareholders was 717.57 million yuan, up 56.18% from the previous year [5][6] - The company's net assets increased by 2.56% to 30.05 billion yuan, while total assets rose by 2.44% to 49.00 billion yuan [5][6] Business Segments Overview Pharmaceutical and Medical - The pharmaceutical segment, primarily through Cheng Da Biological, faced intense competition in the human vaccine market, leading to a revenue decline of 19.74% to 707 million yuan [6][7] - Cheng Da Biological maintains a leading position in the rabies vaccine market, with ongoing development of various vaccine products [6][10] Financial Investment - The financial investment segment saw significant growth, with investment income from Guangfa Securities increasing by 53.19% to 1.08 billion yuan [6][7] - The insurance sector also performed well, with China United Insurance's investment income rising by 143.94% [6][7] Domestic and International Trade - The trade segment achieved a revenue of 4.63 billion yuan, a growth of 3.20%, driven by strong performance in textile and apparel exports [6][7] - The company focused on risk management and operational stability amid fluctuating commodity prices [6][7] Energy Development - The energy segment reported a revenue of 133,000 yuan, with a net loss of 329 million yuan due to extended production halts and regulatory challenges [6][7] - The company is working on obtaining necessary permits for mining operations to resume production [6][7] Market Conditions - The overall economic environment is characterized by slow growth and increased uncertainty, with domestic demand remaining insufficient [6][7] - The pharmaceutical industry is under pressure due to increased competition and declining vaccination rates among the population [6][7] - The financial services sector is expected to continue benefiting from China's economic development and reforms [6][7]

Core Viewpoint - The financial performance of Liaoning Chengda Co., Ltd. shows a significant increase in net profit and total profit for the first half of 2025, despite a slight decrease in revenue compared to the previous year [1][2]. Financial Summary - Total assets at the end of the reporting period reached approximately 49.00 billion RMB, an increase of 2.44% from the previous year [1]. - Net assets attributable to shareholders increased to approximately 30.05 billion RMB, reflecting a growth of 2.56% year-on-year [1]. - Operating revenue for the period was approximately 5.35 billion RMB, down by 0.83% compared to the same period last year [1]. - Total profit for the period was approximately 816.12 million RMB, representing a substantial increase of 65.64% year-on-year [1]. - Net profit attributable to shareholders was approximately 717.57 million RMB, up by 56.18% compared to the previous year [1]. - The net profit after deducting non-recurring gains and losses was not specified [1]. - The net cash flow from operating activities was approximately -139.97 million RMB, showing an improvement from -155.57 million RMB in the previous year [1]. - The weighted average return on equity increased to 2.42%, up by 0.85 percentage points from the previous year [1]. - Basic and diluted earnings per share were both 0.4714 RMB, an increase of 56.20% year-on-year [1]. Shareholder Information - The total number of shareholders at the end of the reporting period was 66,011 [1]. - The largest shareholder, Shaoguan Gaoteng Enterprise Management Co., Ltd., holds 16.20% of the shares, with a total of approximately 247.77 million shares [2]. - Other significant shareholders include Guangxi Xinyi Xin Business Service Co., Ltd. with 8.52% and Jilin Aodong Pharmaceutical Group Co., Ltd. with 6.75% [2]. Debt Financing - The company has issued various debt instruments, including corporate bonds and short-term financing bonds, with interest rates ranging from 2.50% to 5.70% [3]. - The debt-to-asset ratio at the end of the reporting period was 32.61%, slightly up from 32.31% at the end of the previous year [3]. - The EBITDA interest coverage ratio improved to 4.04 from 2.98 in the previous year [3].

General Overview - The document outlines the major event reporting system of Liaoning Chengda Co., Ltd, aiming to standardize the management of significant events and ensure timely, accurate, and comprehensive information disclosure [1][2]. Reporting Obligations - The reporting obligations apply to various company personnel, including directors, senior management, and those in charge of subsidiaries, who must report significant events to the board secretary and chairman [1][2][3]. - The board secretary is responsible for organizing and coordinating the company's information disclosure affairs and is the main person for summarizing internal reports of significant information [2][3]. Scope of Major Events - Major events include significant transactions, related party transactions, major lawsuits, performance forecasts, stock price fluctuations, and any events that may pose significant risks to the company [3][4]. - Specific reporting criteria include transactions exceeding 10% of the company's value or significant lawsuits exceeding 10 million yuan [3][4]. Internal Reporting Procedures - Personnel with reporting obligations must notify the board secretary on the same day they become aware of significant events, using various communication methods [5][6]. - The board secretary must analyze and determine which matters require board or shareholder meeting review and ensure compliance with relevant laws and regulations [6][7]. Responsibilities and Penalties - All departments and subsidiaries must adhere strictly to the reporting system, with penalties for failing to report significant events, including criticism, warnings, economic penalties, or even legal responsibility [8][9]. - Information must not be disclosed externally before it is officially released, and any unauthorized disclosure is prohibited [8][9].